TNF and non-Hodgkin lymphoma: Although infliximab (a monoclonal antibody against TNF-α) has been commonly shown to be effective in AS treatment, long-term follow-up studies demonstrated the association between infliximab therapy and increased risk of non-Hodgkin’s lymphoma (23).